1 active not recruiting, 1 suspended, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Suspended 1, Withdrawn 1 |
Follow David Wald: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | David Wald | 2025-09-01 | 2026-05-13 | |
| Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide - Non Hodgkin Lymphoma | Phase 1 | Active not recruiting | David Wald | 21 | 2023-04-26 | 2026-05-05 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
Cyclophosphamide (3) · fludarabine (2) · fludarabine phosphate (2) · IL32 protein, human (1) · Interleukin-2 (1) · aldesleukin (1) · vactosertib (1)
United States (3)
Benjamin Tomlinson, MD (1) · Changchun Deng, MD, PhD (1) · James Ignatz-Hoover, MD, PhD (1)